Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318565 · ClinicalTrials.gov registry record · Phase 4
Catheter Evaluation for Endocardial Ablation in Patients With Typical Atrial Flutter
A Phase 4 study, sponsored by Biosense Webster.
- Completed
- Registry status
- Phase 4
- Development phase
- 291
- Enrollment target
NCT00318565 is a Phase 4 study that has completed, run by Biosense Webster. The registered enrollment target is 291 participants.
The verdict
NCT00318565, a Phase 4 study, has completed, sponsored by Biosense Webster.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 291 participants
- Enrollment target
Study Summary
The primary objective is to provide additional corroborative safety and efficacy data for the Navistar Thermocool catheter for the treatment of subjects with typical atrial flutter (AFL).
Interventions
- DEVICE RF energy delivery for treatment of Typical Atrial flutter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00318565
The ClinicalTrials.gov registry entry for NCT00318565 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 291 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biosense Webster, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RF energy delivery for treatment of Typical Atrial flutter is the first listed.
NCT00318565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00318565 about?
NCT00318565 is a clinical study titled "Catheter Evaluation for Endocardial Ablation in Patients With Typical Atrial Flutter". The primary objective is to provide additional corroborative safety and efficacy data for the Navistar Thermocool catheter for the treatment of subjects with typical atrial flutter (AFL).
What is the current status of trial NCT00318565?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 291 participants. The study started on 2006-01. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00318565?
The interventions under investigation include: RF energy delivery for treatment of Typical Atrial flutter (DEVICE).
Who is sponsoring clinical trial NCT00318565?
This trial is sponsored by Biosense Webster, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.